Las Vegas, NV -- (SBWIRE) -- 01/04/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Immunomedics, Inc.(NASDAQ:IMMU), Repligen Corporation(NASDAQ:RGEN), Goodrich Petroleum Corporation(NYSE:GDP), Orexigen Therapeutics, Inc.(NASDAQ:OREX)
Immunomedics, Inc.(NASDAQ:IMMU) was a volume gainer of 1.67 million shares and the average volume of the stock remained 880,740.00 shares. The stock opened the session at $4.75 and finished at the end of the day at $4.91 and the stock escalated 6.74%.The market capitalization of the stock remained 408.19 million. Immunomedics, Inc. is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. Epratuzumab's advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE (lupus)), in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL).
For How Long IMMU will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Repligen Corporation(NASDAQ:RGEN) exchanged 1.65 million shares and the average volume remained 420,017.00 shares. The stock closed the session at $12.63 with the drop of -7.40%. Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. The Company develops and markets a series of OPUS (Open Platform User Specified) single-use chromatography columns used in the biologics purification process.
Why Should Investors Buy RGEN After the Recent Fall? Just Go Here and Find Out
Goodrich Petroleum Corporation(NYSE:GDP) decreased -4.76% and its closing price was $16.21. The volume of the stock was 1.65 million shares and the average volume remained 1.97 million shares. The market capitalization of the stock remained 707.94 million. The beta of the stock remained 1.78. Goodrich Petroleum Corporation is an independent oil and natural gas company engaged in exploration, development and production of oil and natural gas on properties primarily in Northwest Louisiana, East Texas and South Texas.
Will GDP Get Buyers Even After The Recent Rally? Find Out Here
Orexigen Therapeutics, Inc.(NASDAQ:OREX) exchanged 1.65 million shares in the previous trading session, and its average trading remained 3.10 million shares. OREX advanced 2.84% and it closed the trading at $5.79. The market capitalization of the stock remained 586.95 million. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
For How Long OREX’s Gloss will Attract Investors? Find out via this report
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)